CYP2C9 Cytochrome P450 2C9
CYP2C9 (Cytochrome P450 2C9): 14 variants described, covering drug response, health risk, nutrition; CPIC pharmacogenomic guidance available.
CYP2C9 and medicines
CYP2C9 is a pharmacogene with CPIC guidance. Star alleles, metaboliser phenotypes and the drugs affected are on the CYP2C9 pharmacogenomics page.
Which CYP2C9 variants does Orviva describe?
- rs1057910 Drug response
- CYP2C9*3 carrier. Reduced metabolism of warfarin, NSAIDs, and oral hypoglycemics.
- rs1799853 Drug response
- CYP2C9*2 carrier. Reduced metabolism of warfarin, NSAIDs, and phenytoin; lower dose may be needed.
- rs7900194 Drug response
- CYP2C9*8 homozygous (R150H). Decreased CYP2C9 function; common in African populations. Affects warfarin dosing.
- rs9332131 Drug response
- CYP2C9*6 carrier (818delA frameshift). Loss of CYP2C9 function; affects warfarin, phenytoin metabolism.
- rs9332239 Drug response
- CYP2C9*12 homozygous (P489S). Decreased CYP2C9 function.
9 further CYP2C9 variants in the knowledge base have only a brief annotation and are not listed here.
Upload your 23andMe, AncestryDNA or WeGene raw file → · Ask G2: “What do my CYP2C9 variants say about me?”
Genetic associations describe risk across populations, not a diagnosis for any one person. Most variants shift risk modestly and act alongside lifestyle, environment and other genes. Consumer DNA chips do not read every position and can be wrong at any single one. For general education only; talk to a clinician or genetic counsellor before acting on anything here, and never change a prescribed medicine without your prescriber.